Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are now established first-line options for EGFR mutation positive non-small cell lung cancer (NSCLC). While the first (1G) ...